nature portfolio

Corresponding author(s):

Matt J Keeling, Louise Dyson, Michael J Tildesley, Edward M Hill, Samuel Moore

Last updated by author(s): Jun 27, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Со	nfirmed
\boxtimes		The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
\boxtimes		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
\boxtimes		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes		A description of all covariates tested
\square		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	\boxtimes	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes		For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
\square		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about <u>availability of computer code</u>						
Data collection	No software was used for data collection					
Data analysis	Code used to generate model results has been made available at: https://github.com/MattKeeling/RelaxationRoadmaps.git Keeling MJ, Dyson L, Tildesley MJ, Hill EM, Moore S. Comparison of the 2021 COVID-19 Roadmap Projections against Public Health Data in England, Repository name: MattKeeling/RelaxationRoadmaps. URL https://doi.org/10.5281/zenodo.6756994. (2022).					

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Data on cases were obtained from the COVID-19 Hospitalisation in England Surveillance System (CHESS) data set that collects detailed data on patients infected with COVID-19. Data on COVID-19 deaths were obtained from Public Health England. These data contain confidential information, with public data deposition

nonpermissible

for socioeconomic reasons. The CHESS data resides with the National Health Service (www.nhs.gov.uk) whilst the death data are available from Public Health England (www.phe.gov.uk). The ethics of the use of these data for these purposes was agreed by Public Health England with the Governments SPI-M-O / SAGE committees. More aggregate data is freely available from the UK Coronavirus dashboard: https://coronavirus.data.gov.uk/

Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

	Life	scie	nces
--	------	------	------

Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	The data used is the complete information on cases (positive and negative tests), hospital admissions and deaths in England over the COVID-19 pandemic. Therefore there is not sample size (unless it is the population size of England).
Data exclusions	No data were excluded
Replication	The model uses data from a single epidemic outbreak - so replication is not appropriate. Some model validity work was conducted using slightly different model formulations, without producing a qualitative change in projections.
Randomization	Given this is not a case-control experiment (we are not comparing the outcome of two or more effects) then randomization of the data is not appropriate.
Blinding	Given this is not a case-control experiment then blinding of the data is not appropriate.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems Methods Involved in the study Involved in the study n/a n/a \boxtimes ChIP-seq \boxtimes Antibodies \boxtimes Eukaryotic cell lines \boxtimes Flow cytometry \bowtie Palaeontology and archaeology \boxtimes MRI-based neuroimaging Animals and other organisms \boxtimes Clinical data \boxtimes \boxtimes Dual use research of concern